Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
3 hedge funds and large institutions have $177K invested in Progenics Pharmaceuticals Inc in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 126 closing their positions.
98% less funds holding
Funds holding: 129 → 3 (-126)
100% less capital invested
Capital invested by funds: $222M → $177K (-$222M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 126
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$52.6M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$31.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$21.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$17.6M |
PGNX Hedge Fund Activity: Q2 2020 in Review
3 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2020, worth a combined $177K — down 100% from $222M a quarter earlier.
Sellers outnumbered buyers: 126 funds closed out of PGNX and 0 opened new positions — a net loss of 126 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $52.6M sold.
- 3 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2020, down from 129 in Q1 2020.
- Funds reported $177K of Progenics Pharmaceuticals Inc stock for Q2 2020, down 100% quarter-over-quarter.
- 0 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2020 and 126 closed out, a net change of -126 holders.
- The largest Progenics Pharmaceuticals Inc seller in Q2 2020 was BlackRock, an estimated $52.6M sold.
Based on aggregated 13F filings for Q2 2020.